These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth. Edupuganti R; Taliaferro JM; Wang Q; Xie X; Cho EJ; Vidhu F; Ren P; Anslyn EV; Bartholomeusz C; Dalby KN Bioorg Med Chem; 2017 May; 25(9):2609-2616. PubMed ID: 28351607 [TBL] [Abstract][Full Text] [Related]
5. Tinker-OpenMM: Absolute and relative alchemical free energies using AMOEBA on GPUs. Harger M; Li D; Wang Z; Dalby K; Lagardère L; Piquemal JP; Ponder J; Ren P J Comput Chem; 2017 Sep; 38(23):2047-2055. PubMed ID: 28600826 [TBL] [Abstract][Full Text] [Related]
7. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach. Shafique S; Bibi N; Rashid S J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360 [TBL] [Abstract][Full Text] [Related]
8. Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors. Xiong W; Matheson CJ; Xu M; Backos DS; Mills TS; Salian-Mehta S; Kiseljak-Vassiliades K; Reigan P; Wierman ME Mol Cancer Ther; 2016 Mar; 15(3):412-20. PubMed ID: 26721946 [TBL] [Abstract][Full Text] [Related]
9. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations. Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584 [TBL] [Abstract][Full Text] [Related]
10. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. Cho YS; Kang Y; Kim K; Cha YJ; Cho HS Biochem Biophys Res Commun; 2014 Apr; 447(1):7-11. PubMed ID: 24657156 [TBL] [Abstract][Full Text] [Related]
11. Exploring the stability of inhibitor binding to SIK2 using molecular dynamics simulation and binding free energy calculation. Shi M; Zhao M; Wang L; Liu K; Li P; Liu J; Cai X; Chen L; Xu D Phys Chem Chem Phys; 2021 Jun; 23(23):13216-13227. PubMed ID: 34086021 [TBL] [Abstract][Full Text] [Related]
12. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity. Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550 [TBL] [Abstract][Full Text] [Related]
13. Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight. Touré BB; Giraldes J; Smith T; Sprague ER; Wang Y; Mathieu S; Chen Z; Mishina Y; Feng Y; Yan-Neale Y; Shakya S; Chen D; Meyer M; Puleo D; Brazell JT; Straub C; Sage D; Wright K; Yuan Y; Chen X; Duca J; Kim S; Tian L; Martin E; Hurov K; Shao W J Med Chem; 2016 May; 59(10):4711-23. PubMed ID: 27187609 [TBL] [Abstract][Full Text] [Related]
14. Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. Najjar A; Platzer C; Luft A; Aßmann CA; Elghazawy NH; Erdmann F; Sippl W; Schmidt M Eur J Med Chem; 2019 Jan; 161():479-492. PubMed ID: 30388464 [TBL] [Abstract][Full Text] [Related]
15. Crystal structure of Maternal Embryonic Leucine Zipper Kinase (MELK) in complex with dorsomorphin (Compound C). Rembacz KP; Zrubek KM; Golik P; Michalik K; Bogusz J; Wladyka B; Romanowska M; Dubin G Arch Biochem Biophys; 2019 Aug; 671():1-7. PubMed ID: 31108049 [TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of a Novel PLK1 Inhibitor Scaffold Using a Hybridized 3D-QSAR Model. Oh Y; Jung H; Kim H; Baek J; Jun J; Cho H; Im D; Hah JM Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917995 [TBL] [Abstract][Full Text] [Related]
17. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition. Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604 [TBL] [Abstract][Full Text] [Related]
18. Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases. Zhou X; Yu S; Su J; Sun L Int J Mol Sci; 2016 Mar; 17(3):340. PubMed ID: 26959013 [TBL] [Abstract][Full Text] [Related]
19. Binding free-energy calculation is a powerful tool for drug optimization: calculation and measurement of binding free energy for 7-azaindole derivatives to glycogen synthase kinase-3β. Kitamura K; Tamura Y; Ueki T; Ogata K; Noda S; Himeno R; Chuman H J Chem Inf Model; 2014 Jun; 54(6):1653-60. PubMed ID: 24884406 [TBL] [Abstract][Full Text] [Related]
20. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Chung S; Suzuki H; Miyamoto T; Takamatsu N; Tatsuguchi A; Ueda K; Kijima K; Nakamura Y; Matsuo Y Oncotarget; 2012 Dec; 3(12):1629-40. PubMed ID: 23283305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]